Five-year outcomes of EVO implantable collamer lens implantation for the correction of high myopia and super high myopia

Eye Vis (Lond). 2021 Nov 9;8(1):40. doi: 10.1186/s40662-021-00264-0.

Abstract

Background: To evaluate the long-term safety, efficacy, predictability, and stability of implantable collamer lens with a central hole (EVO ICL) implantation for correcting high myopia (HM) and super high myopia (SHM).

Methods: This prospective study evaluated 83 eyes of 46 patients who were divided into groups based on their spherical equivalent refractive error (SE): HM group (- 12 D ≤ SE < - 6 D) and SHM group (SE < - 12 D). They were followed up for 5 years after ICL implantation; assessments of uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refractive error, axial length, intraocular pressure, corneal endothelial cell density, and vault were conducted, and a questionnaire was administered.

Resuits: At 5 years postoperatively, the safety indices of the HM and SHM groups were 1.03 ± 0.10 and 1.32 ± 0.39, and the efficacy indices were 0.83 ± 0.25 and 0.86 ± 0.32, respectively. In the HM group, 60.47% and 79.07% of the eyes were within ± 0.50 D and ± 1.00 D of the attempted correction, while it was achieved for 22.50% and 47.50% of the eyes in the SHM group, respectively. The SE of the HM group decreased from - 9.72 ± 1.41 D preoperatively to 0.04 ± 0.39 D 1 month postoperatively and - 0.67 ± 0.57 D 5 years postoperatively, while in the SHM group, it decreased from - 15.78 ± 3.06 D preoperatively to - 0.69 ± 0.97 D 1 month postoperatively and - 1.74 ± 1.19 D 5 years postoperatively.

Conclusion: EVO ICL implantation is safe, effective, and predictable for correcting HM and SHM. CDVA improved more after surgery for SHM, but the growth of axial length still needs attention.

Keywords: EVO ICL; High myopia; Posterior chamber phakic intraocular lens implantation; Super high myopia.